Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

TCT 2021 | Outcomes of alloHCT in adults with Ph-like ALL

Ibrahim Aldoss, MD, City of Hope National Medical Center, Duarte, CA, discusses the outcomes of allogeneic hematopoietic cell transplantation (alloHCT) in adults with Philadelphia-like (Ph-like) acute lymphoblastic leukemia (ALL). In this cohort, alloHCT was associated with a three-year survival rate of 55%; survival outcomes did not differ between Ph-like and non-Ph-like ALL. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.